These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 8309031)

  • 1. Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary.
    Chren MM; Landefeld CS
    JAMA; 1994 Mar; 271(9):684-9. PubMed ID: 8309031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions between physicians and the pharmaceutical industry: what does the literature say?
    Lexchin J
    CMAJ; 1993 Nov; 149(10):1401-7. PubMed ID: 8221424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physicians and the pharmaceutical industry: is a gift ever just a gift?
    Wazana A
    JAMA; 2000 Jan; 283(3):373-80. PubMed ID: 10647801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating a restrictive formulary system by assessing nonformulary-drug requests.
    Green JA; Chawla AK; Fong PA
    Am J Hosp Pharm; 1985 Jul; 42(7):1537-41. PubMed ID: 4025350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks.
    Hodges B
    CMAJ; 1995 Sep; 153(5):553-9. PubMed ID: 7641153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with physicians' reliance on pharmaceutical sales representatives.
    Anderson BL; Silverman GK; Loewenstein GF; Zinberg S; Schulkin J
    Acad Med; 2009 Aug; 84(8):994-1002. PubMed ID: 19638762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors that influence patient response to requests to change to a unified restrictive formulary.
    Smetana GW; Davis RB; Phillips RS
    J Gen Intern Med; 2004 Dec; 19(12):1212-9. PubMed ID: 15610332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A population-based study of the prevalence and influence of gifts to radiation oncologists from pharmaceutical companies and medical equipment manufacturers.
    Halperin EC; Hutchison P; Barrier RC
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1477-83. PubMed ID: 15275735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulary decision making: identifying factors that influence P&T committee drug evaluations.
    Segal R; Pathak DS
    Hosp Formul; 1988 Feb; 23(2):174-8. PubMed ID: 10286022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physician satisfaction with formulary policies: is it access to formulary or nonformulary drugs that matters most?
    Glassman PA; Good CB; Kelley ME; Bradley M; Valentino M
    Am J Manag Care; 2004 Mar; 10(3):209-16. PubMed ID: 15032258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical communication companies and industry grants.
    Rothman SM; Brudney KF; Adair W; Rothman DJ
    JAMA; 2013 Dec; 310(23):2554-8. PubMed ID: 24346991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physician-hospital conflict among salaried physicians.
    Noy S; Lachman R
    Health Care Manage Rev; 1993; 18(4):60-9. PubMed ID: 8282548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between physicians and pharmaceutical representatives, an insight from Thailand.
    Srinonprasert V; Arrunyagasamesuke A; Nimmannit A; Sutheechet K; Wongwatcharadeth P; Phattharayuttawat S; Pongprasobchai S
    J Med Assoc Thai; 2014 Mar; 97 Suppl 3():S223-31. PubMed ID: 24772602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical students' exposure to and attitudes about drug company interactions: a national survey.
    Sierles FS; Brodkey AC; Cleary LM; McCurdy FA; Mintz M; Frank J; Lynn DJ; Chao J; Morgenstern BZ; Shore W; Woodard JL
    JAMA; 2005 Sep; 294(9):1034-42. PubMed ID: 16145023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marketing pharmaceutical products to physicians. Sales reps influence physicians' impressions of the industry.
    Creyer EH; Hrsistodoulakis I
    Mark Health Serv; 1998; 18(2):34-8. PubMed ID: 10180333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Giving and receiving of gifts between pharmaceutical companies and medical specialists in Australia.
    McNeill PM; Kerridge IH; Henry DA; Stokes B; Hill SR; Newby D; Macdonald GJ; Day RO; Maguire J; Henderson KM
    Intern Med J; 2006 Sep; 36(9):571-8. PubMed ID: 16911549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Legislative, educational, policy and other interventions targeting physicians' interaction with pharmaceutical companies: a systematic review.
    Alkhaled L; Kahale L; Nass H; Brax H; Fadlallah R; Badr K; Akl EA
    BMJ Open; 2014 Jul; 4(7):e004880. PubMed ID: 24989618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National survey on the attitudes of Canadian physicians towards drug-detailing by pharmaceutical representatives.
    Strang D; Gagnon M; Molloy W; Bedard M; Darzins P; Etchells E; Davidson W
    Ann R Coll Physicians Surg Can; 1996 Dec; 29(8):474-8. PubMed ID: 12380577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for deleting popular drugs from a hospital formulary.
    Lemay AP; Salzer LB; Visconti JA; Latiolais CJ
    Am J Hosp Pharm; 1981 Apr; 38(4):506-10. PubMed ID: 7282675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ohio hospital formularies: an analysis of structure, process, and outcome.
    Parrish RH; Berger BA
    Hosp Pharm; 1985 Aug; 20(8):600-3, 606-11. PubMed ID: 10289647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.